← All trials
NCT02921373
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2019
- Primary completion
- Jun 30, 2022
- Completion date
- Dec 31, 2022
- First posted
- Oct 3, 2016
- Last posted
- May 24, 2018
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Western OntarioLead sponsor
- Ontario Institute for Cancer ResearchCollaborator
- University of TorontoOverall official - principal investigator
- University of Western OntarioCollaborator
- University of Western OntarioStudy chair
- University of Western OntarioSponsor investigator
- University of TorontoOfficial
- University of Western OntarioOfficial
- University of Western OntarioOfficial
- University of Western OntarioOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.